Transaction details
Alignment Healthcare (NASDAQ:ALHC) Chief Information Officer Robert L. Scavo executed a sale of 11,285 shares of common stock on March 18, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares moved at a weighted-average price of $17.84, producing total proceeds of $201,324. The reported sale prices ranged between $17.40 and $18.24 per share.
Following the transaction, Scavo directly holds 487,685 shares of Alignment Healthcare. Company filings indicate the disposition was carried out to cover tax withholding obligations associated with the vesting of restricted stock units and was not a discretionary sale.
Market snapshot
At the time of the filing, Alignment Healthcare shares were trading at $18.16 and the company’s market capitalization was listed at $3.76 billion.
Analyst and proprietary research notes
Analysis available via InvestingPro characterized the stock as appearing undervalued at prevailing levels and included a fiscal 2026 EPS forecast of $0.46. The same platform referenced Pro Research Reports covering ALHC among a broader US equity universe. Those assessments and reports are presented as informational resources for investors.
Recent company performance
Alignment Healthcare’s most recent fourth-quarter financials showed notable top-line and membership expansion. The company reported roughly 44.4% year-over-year revenue growth and approximately 25% growth in membership. In the quarter, the medical benefit ratio (MBR) was reported at 87.7%, and the selling, general, and administrative (SG&A) expense ratio improved by about 115 basis points to 9.7%.
Following those results, Raymond James maintained a Strong Buy rating with a $27.00 price target, while Piper Sandler kept an Overweight rating and a $30.00 price target.
Secondary offering by General Atlantic affiliate
Separately, Alignment Healthcare disclosed a secondary offering of 13.2 million shares by an affiliate of General Atlantic, L.P., priced at $19.46 per share. The company clarified that it will not receive any proceeds from this transaction because the offering is being conducted by the selling stockholder. The offering was expected to close on March 4, 2026, with J.P. Morgan acting as underwriter.
Context and closing
Taken together, the insider sale to meet tax obligations, recent financial results, analyst ratings, and the selling-stockholder secondary offering form the immediate set of disclosures and market-moving items around Alignment Healthcare. Each item is reported from company filings, analyst notes, and regulatory forms filed with the SEC.